201 related articles for article (PubMed ID: 12057049)
21. Bisphosphonates in multiple myeloma.
Berenson JR
Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
[TBL] [Abstract][Full Text] [Related]
22. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
23. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
Grannis CH; Dewan VN; Wang RC
Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; López Corral L; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Olavarría E; Quintana N; García JL; Bladé J; Lahuerta JJ; San Miguel JF
N Engl J Med; 2013 Aug; 369(5):438-47. PubMed ID: 23902483
[TBL] [Abstract][Full Text] [Related]
25. Update on the treatment of multiple myeloma.
Kyle RA
Oncologist; 2001; 6(2):119-24. PubMed ID: 11306723
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
27. Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
[TBL] [Abstract][Full Text] [Related]
28. New approaches to smoldering myeloma.
Mateos MV; San Miguel JF
Curr Hematol Malig Rep; 2013 Dec; 8(4):270-6. PubMed ID: 23975678
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of multiple myeloma].
Harousseau JL
Schweiz Med Wochenschr; 2000 Nov; 130(44):1649-55. PubMed ID: 11103435
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
31. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide in the management of multiple myeloma.
Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G
Semin Hematol; 2001 Jul; 38(3):250-9. PubMed ID: 11486313
[TBL] [Abstract][Full Text] [Related]
33. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
34. Newer approaches to the management of multiple myeloma.
Kyle RA
Cancer; 1993 Dec; 72(11 Suppl):3489-94. PubMed ID: 8242581
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
36. Novel approaches in myeloma therapy.
Munshi NC; Barlogie B; Desikan KR; Wilson C
Semin Oncol; 1999 Oct; 26(5 Suppl 13):28-34. PubMed ID: 10528892
[TBL] [Abstract][Full Text] [Related]
37. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
Lust JA; Lacy MQ; Zeldenrust SR; Dispenzieri A; Gertz MA; Witzig TE; Kumar S; Hayman SR; Russell SJ; Buadi FK; Geyer SM; Campbell ME; Kyle RA; Rajkumar SV; Greipp PR; Kline MP; Xiong Y; Moon-Tasson LL; Donovan KA
Mayo Clin Proc; 2009 Feb; 84(2):114-22. PubMed ID: 19181644
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic application of thalidomide in multiple myeloma.
Kyle RA; Rajkumar SV
Semin Oncol; 2001 Dec; 28(6):583-7. PubMed ID: 11740813
[TBL] [Abstract][Full Text] [Related]
39. Newly diagnosed multiple myeloma.
Weber DM
Curr Treat Options Oncol; 2002 Jun; 3(3):235-45. PubMed ID: 12057069
[TBL] [Abstract][Full Text] [Related]
40. Management of asymptomatic myeloma patients.
Mateos MV
Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]